These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 22836615

  • 21. Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials.
    Park J, Lee JS, Rhee C, Oh YM.
    J Korean Med Sci; 2015 Oct; 30(10):1453-8. PubMed ID: 26425042
    [Abstract] [Full Text] [Related]

  • 22. Indacaterol therapy in patients with COPD not receiving other maintenance treatment.
    Decramer M, Rossi A, Lawrence D, McBryan D.
    Respir Med; 2012 Dec; 106(12):1706-14. PubMed ID: 23031496
    [Abstract] [Full Text] [Related]

  • 23. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
    Ridolo E, Montagni M, Riario-Sforza GG, Baroni M, Incorvaia C.
    Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
    [Abstract] [Full Text] [Related]

  • 24. Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol.
    Feldman GJ.
    Int J Chron Obstruct Pulmon Dis; 2013 Apr; 8():89-96. PubMed ID: 23431038
    [Abstract] [Full Text] [Related]

  • 25. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
    Gotfried MH, Kerwin EM, Lawrence D, Lassen C, Kramer B.
    COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
    [Abstract] [Full Text] [Related]

  • 26. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial.
    Santus P, Radovanovic D, Di Marco S, Valenti V, Raccanelli R, Blasi F, Centanni S, Bussotti M.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec; 10():1917-23. PubMed ID: 26392766
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
    Wedzicha JA, Buhl R, Lawrence D, Young D.
    Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Indacaterol: a comprehensive review.
    Rossi A, Polese G.
    Int J Chron Obstruct Pulmon Dis; 2013 Jan; 8():353-63. PubMed ID: 23922496
    [Abstract] [Full Text] [Related]

  • 35. Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.
    Mahler DA, Kerstjens HA, Donohue JF, Buhl R, Lawrence D, Altman P.
    Respir Med; 2015 Aug; 109(8):1031-9. PubMed ID: 26094050
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium.
    Rossi A, Centanni S, Cerveri I, Gulotta C, Foresi A, Cazzola M, Brusasco V.
    Respir Med; 2012 Jan; 106(1):84-90. PubMed ID: 22035851
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.